Patent · US Active

Tissue-specific genome engineering using CRISPR-Cas9

US10851367B2 · kind B2 · utility

1Cited by

0References

20Claims

0Family size

Assignees

PFIZER INC. · US
The Regents of the University of California · US

Inventors

Spiros Liras · Stonington, US
Vincent Mascitti · Groton, US
Benjamin Thuma · Old Lyme, US
Jennifer A. Doudna · Berkeley, US
Romain Rouet · Berkeley, US

Key dates

Filing date	Nov 9, 2016
Grant date	Dec 1, 2020
Priority date	—
Expiry date	Sep 4, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/907
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.